MedTrace Logo

Diagnostic Investigation of Sudden Cardiac Event Risk

NCT00500708 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1564

Last updated 2017-10-19

No results posted yet for this study

Summary

The overall objective of the DISCERN study is to develop and validate a genomic diagnostic assay to identify patients at increased risk for lethal ventricular arrhythmias and sudden cardiac death (SCD).

Conditions

Sponsors & Collaborators

  • CardioDx

    lead INDUSTRY

Principal Investigators

  • Michael Zapien, MS · CardioDx, Inc.

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2011-08-01
Completion
2011-08-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00500708 on ClinicalTrials.gov